HL-400 Trial
Phase 1
54
about 10 months
18–65
1 site in MD
About this study
Researchers are testing a new drug called HL-400 in people with Parkinson's Disease. The trial will evaluate the safety and how the body processes HL-400 after taking it as a single dose or multiple doses over 308 days.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take HL-400
- 2.Take Placebo
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Primary: Change in 12-lead electrocardiogram (ECG) parameters (PR Interval, QRS Complex, QT Interval, QTC Interval) from baseline, Multiple Ascending Dose (MAD) Cohorts: Maximum observed plasma concentration (Cmax) of HL-400, Number and percentage of adverse events (AEs) according to severity, Number and percentage of participants with adverse events (AEs), Single Ascending Dose (SAD) Cohorts: Maximum observed plasma concentration (Cmax) of HL-400, Single Ascending Dose (SAD) Cohorts: Plasma decay half-life (t1/2) of HL-400, Single Ascending Dose (SAD) Cohorts: Time to reach maximum observed plasma concentration (Tmax) of HL-400
Secondary: 1.The cerebrospinal fluid (CSF) cohort: Maximum observed concentration (Cmax) of HL-400 in the CSF
Neurology